Circulating burst-forming-unit erythroid and the responsiveness to recombinant human erythropoietin in patients on regular hemodialytic treatment

C. Brunati, M. D. Cappellini, T. De Feo, I. Stefanoni, G. Civati, L. Ballerini, G. Fiorelli, L. Minetti

Research output: Contribution to journalArticle

Abstract

The dose of recombinant human erythropoietin (r-HuEpo) required to correct anemia of end-stage renal disease varies among patients. The possible factors that interfere with the responsiveness to r-HuEpo were not completely known. In 32 patients on regular hemodialytic treatment with marked anemia (Hb 5.6 ± 0.7 g/dl), we evaluated circulating erythroid progenitor cells [burst-forming-unit erythroid (BFU-E)], erythropoietin, ferritin, folate and 1-84-parathormone levels before r-HuEpo therapy. In 12 patients, the aluminum levels after deferoxamine were also evaluated. The possible correlation between these factors and the response to r-HuEpo therapy was then evaluated. The number of circulating (c) BFU-E was highly variable (521 ± 447 colonies/ml of blood; normal level 742 ± 192) and does not correlate with erythropoietin, ferritin, folate, 1-84-parathormone or aluminum levels. A direct correlation between basal cBFU-E and the responsiveness to r-HuEpo therapy was recorded while no correlation was found with the other analyzed parameters. We hypothesized that low basal cBFU-E (interleukin-3 deficiency?) could reduce the response to r-HUEpo because of failure of this hematopoietic stem cell compartment to replenish the pool of more mature erythropoietic progenitor cells during the phase of accelerated maturation induced by r-HuEpo.

Original languageEnglish
Pages (from-to)150-154
Number of pages5
JournalNephron
Volume62
Issue number2
Publication statusPublished - 1992

Keywords

  • Burst-forming-unit erythroid
  • Erythropoietin
  • Renal anemia

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Circulating burst-forming-unit erythroid and the responsiveness to recombinant human erythropoietin in patients on regular hemodialytic treatment'. Together they form a unique fingerprint.

  • Cite this